Aberdeen Group
AVTX icon

Aberdeen Group’s Avalo Therapeutics AVTX Stock Holding History

Aberdeen Group’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Sell
122,169
-49,510
-29% -$783K ﹤0.01% 764
2026
Q1 		$2.56M Buy
171,679
+76,253
+80% +$1.19M ﹤0.01% 750
2025
Q4 		$1.73M Buy
95,426
+22,626
+31% +$382K ﹤0.01% 796
2025
Q3 		$925K Buy
+72,800
New +$626K ﹤0.01% 841

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Aberdeen Group's AVTX Position: Q2 2026 in Review

Aberdeen Group reduced its Avalo Therapeutics (AVTX) stake by 29% in Q2 2026, selling an estimated $783K and leaving 122,169 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #764.

Aberdeen Group first reported a position in AVTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $2.56M in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Aberdeen Group held 122,169 shares of Avalo Therapeutics worth $2.26M as of Q2 2026.
  • Aberdeen Group sold 49,510 Avalo Therapeutics shares in Q2 2026, an estimated $783K.
  • Avalo Therapeutics made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #764 holding.
  • Aberdeen Group first reported a position in Avalo Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Aberdeen Group's Avalo Therapeutics position peaked at $2.56M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.